Kernal Biologics

Kernal Biologics is a biotechnology company located in Cambridge, Massachusetts, that specializes in mRNA 2.0 immunotherapies for cancer and autoimmune diseases. Founded in 2016, the company utilizes advanced selective mRNA-lipid nanoparticle (LNP) technology to deliver therapeutic mRNAs directly to targeted cells, enhancing treatment efficacy while minimizing off-target effects. The company's lead program, KR-402, demonstrates their innovative approach by achieving over 90% delivery efficiency to T-cells, enabling *in vivo* CAR-T cell programming. This method aims to address the challenges of current cell therapies, which can be slow and costly. Kernal Biologics also has a pipeline of additional programs, including KR-335, and offers licensing opportunities for its unlicensed products. The management team comprises experts from prestigious institutions and companies, and the company is backed by notable investors.